Related Experiment Video
Updated: Feb 26, 2026

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies
Geoffrey A Pietersz1,2,3,4, Xiaowei Wang1,5, May Lin Yap1,4
1Baker IDI Heart & Diabetes Institute, Melbourne, Australia.
Abstract:
The unique chemical and functional properties of nanoparticles can be harnessed for the delivery of large quantities of various therapeutic biomolecules. Active targeting of nanoparticles by conjugating ligands that bind to target cells strongly facilitates accumulation, internalization into target cells and longer retention at the target site, with consequent enhanced therapeutic effects. Recombinant antibodies with high selectivity and availability for a vast range of targets will dominate the future. In this review, we systematically outline the tremendous progress in the conjugation of antibodies to nanoparticles and the clear advantages that recombinant antibodies offer in the therapeutic targeting of nanoparticles. The demonstrated flexibility of recombinant antibody coupling to nanoparticles highlights the bright future of this technology for modern therapeutic nanomedicine.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Modified-Release Drug Delivery Systems: Site-Targeted
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Recombinant DNA
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

